Quartz Bio becomes part of Precision Medicine Group

Biomarker research has become critical to the development of innovative treatments, including predicting relevant clinical outcomes across a variety of treatments and populations. However, researchers continue to struggle to organize and interrogate these highly dense and expansive data sets.

Precision’s new Geneva team is a unique and diverse group of experienced data scientists, computational biologists, computational immunologists, and translational informaticians. These computational and data science experts join Precision’s existing translational informatics team to provide unrivaled biomarker data management and translational informatics services to facilitate translational research for innovative pharma and biotech clients, both in Europe and the United States.

Mark P. Clein, CEO of Precision Medicine Group, became President of the Board of Quartz Bio, John Mariano, Senior VP & General Counsel of Precision Medicine Group became Vice President of the Board. Dr. Jerome Wojcik was named Senior Vice President, Translational Informatics and Biometrics, Europe, and will lead the new team in Switzerland.

The Geneva office, along with established offices in Berlin, Paris, and Edinburgh, strategically expands Precision’s growing European footprint and further positions the company as a scientific frontrunner in the rapidly expanding precision medicine space.

In addition, Precision announced the release of QuartzBio, the next generation of its proprietary technology platform designed to accelerate translational research. Initially launched in 2014, this latest iteration represents a significant advancement in the support of biomarker data management and translational informatics and actively supports a diverse client base of biopharmaceutical customers. QuartzBio assimilates all biomarker data with extreme speed including high-content to high-throughput data, such as immunosequencing, flow cytometry, and profiling of the transcriptome, and is capable of harmonizing more than 10 million data points.

Commenting on Precision’s expanded European capabilities and release of QuartzBio, Chad Clark, president of Precision for Medicine, said: “We are very excited to be expanding our translational research offering into Europe with the addition of our Geneva office. The unique diversity and scientific expertise of the team is tremendously valuable for our clients. Our global teams together with our technology platform, QuartzBio create a distinctly comprehensive, industry-leading biomarker data management and translational informatics offering for international pharmaceutical innovators who are grappling every day with how best to harmonize and assess highly complex biomarker information.”

About Precision for Medicine
Precision for Medicine supports life sciences companies in the use of biomarkers essential to targeting patients more precisely and effectively. Precision applies novel biomarker approaches to clinical research that take advantage of the latest advancements in science and technology, focusing predominantly on genomics, immune-response assays, global specimen logistics, biomarker analytics, companion diagnostics, and clinical trial execution. Precision for Medicine is part of Precision Medicine Group, with more than 1,000 employees in 22 locations in the US, Canada, and Europe.

(SK)